Cargando…
Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities. We present the first reported case, to our knowledge, of immune-mediated nephritis following the administration of Tremelimumab (C...
Autores principales: | Jolly, Elaine C., Clatworthy, Menna R., Lawrence, Christopher, Nathan, Paul D., Farrington, Ken |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421243/ https://www.ncbi.nlm.nih.gov/pubmed/25984021 http://dx.doi.org/10.1093/ndtplus/sfp048 |
Ejemplares similares
-
Granulomatous interstitial nephritis with CTLA-4 haploinsufficiency: a case report
por: Kohatsu, Kaori, et al.
Publicado: (2022) -
CD152 (CTLA-4) Determines CD4 T Cell Migration In Vitro and In Vivo
por: Knieke, Karin, et al.
Publicado: (2009) -
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011) -
Increased percentage of apoptotic and CTLA-4 (CD152) expressing cells in CD4(+)/CD8(+) cells in COVID-19 patients
por: Zahran, Asmaa M., et al.
Publicado: (2022) -
Decreased CD4+CD152+ T cell subset and its correlation with the level of antithyroid antibodies in children with chronic autoimmune thyroiditis
por: Kucharska, AM, et al.
Publicado: (2010)